Antibodies must be developable and manufacturable say FairJourney and Iontas, the latest partnership aiming to bring a therapy against COVID-19 to fruition. Recently we published a comprehensive guide to all the antibody-based therapies being developed to treat COVID-19, caused by the novel coronavirus (SARS-CoV-2). The latest firms looking to this modality in the battle against the virus are UK-based biotech Iontas and Portugese contract research organization (CRO) FairJourney Biologics, which announced a partnership to combine the latter’s phage display antibody…